Finance

Lists
N1VS34:BVMF
Novartis AG Bdr
R$ ७४.३४
०.००%
(०.००) 1D
अक्टोबर १४, १६:५६:०० GMT-३  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for N1VS34...
Open
R$ ८०.०९
High
R$ ८०.०९
Low
R$ ७३.४३
Mkt. cap
२.५२ खरब
Avg. vol.
२०१.००
Volume
११४.००
52-wk high
R$ ८७.३०
52-wk low
R$ ६५.०३
Shares outstanding
२.०३ अरब
No. of employees
७५ हजार
Open
R$ ८०.०९
High
R$ ८०.०९
Low
R$ ७३.४३
Mkt. cap
२.५२ खरब
Avg. vol.
२०१.००
Volume
११४.००
52-wk high
R$ ८७.३०
52-wk low
R$ ६५.०३
Shares outstanding
२.०३ अरब
No. of employees
७५ हजार
News stories
From web sources and news partners
Global Arbitration Review
Global Arbitration Review
·
१५ घण्टा पहिले
US biotech company enforces eye treatment award against Novartis
Quiver Quantitative
Quiver Quantitative
·
१६ घण्टा पहिले
Why Novartis (NVS) Stock Is Up Today
marketscreener.com
marketscreener.com
·
२ दिन पहिले
Swiss Blue-chip Index Starts Week Upbeat; Roche, Novartis Shares Gain
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG Bdr
CEOVasant Narasimhan
Employees७५.३ हजार
Founded१९९६ मार्च ७
Headquartersबेसेल, Basel City, स्विट्जरल्यान्ड
Sector-
Next call १२ दिनमा
अक्टोबर २७, मङ्गल, १८:४०
Fiscal period
Q3 2026
- / US$ २.२८
Revenue / Est. (USD)
- / १४.६१ अरब
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१४.३६ अरब
१३.८६ अरब
१३.५२ अरब
१४.९५ अरब
Cost of goods sold
३.५४ अरब
३.५४ अरब
३.४४ अरब
३.६८ अरब
Cost of revenue
३.५४ अरब
३.५४ अरब
३.४४ अरब
३.६८ अरब
Research and development expenses
२.८६ अरब
२.८४ अरब
२.७८ अरब
२.७४ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३.३० अरब
३.४४ अरब
३.१४ अरब
३.२३ अरब
Operating expense
६.२४ अरब
६.४६ अरब
५.९६ अरब
६.१० अरब
Total operating expenses
९.७७ अरब
१०.०० अरब
९.४० अरब
९.७८ अरब
Operating income
४.५८ अरब
३.८६ अरब
४.१२ अरब
५.१८ अरब
Other non operating income
-७०.०० लाख
-१३.०० करोड
४०.०० लाख
१.९० करोड
EBT including unusual items
४.२० अरब
३.२२ अरब
३.८४ अरब
४.२७ अरब
EBT excluding unusual items
४.२९ अरब
३.४९ अरब
३.७८ अरब
४.७३ अरब
Income tax expense
२६.६० करोड
८१.४० करोड
६८.३० करोड
१.०१ अरब
Effective tax rate
६.३४%
२५.३०%
१७.७९%
२३.७१%
Other operating expenses
७.०० करोड
१९.०० करोड
४.२० करोड
१२.७० करोड
Net income
३.९३ अरब
२.४१ अरब
३.१६ अरब
३.२६ अरब
Net profit margin
२७.३६%
१७.३८%
२३.३४%
२१.८३%
Earnings per share
२.२५
२.०३
१.९९
२.४१
Interest and investment income
-
३७.३० करोड
-
-
Interest expense
-२८.१० करोड
-३०.४० करोड
-३४.३० करोड
-४६.२० करोड
Net interest expenses
-२८.१० करोड
६.९० करोड
-३४.३० करोड
-४६.२० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
५.७८ अरब
४.९६ अरब
५.२४ अरब
६.३० अरब
Gain or loss from assets sale
८.१० करोड
८.०० करोड
-१५.९० करोड
-२४.७० करोड
AI content may include mistakes. Learn more
Google एपहरू